There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …

Hepatocellular carcinoma is the second most common cause of cancer death in the world
and its incidence has dramatically increased worldwide in the past two decades. Syringic …

Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …

Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Background VEGF and VEGF receptor-2-mediated angiogenesis contribute to
hepatocellular carcinoma pathogenesis. Ramucirumab is a recombinant IgG1 monoclonal …

Summary Background Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved
overall survival and progression-free survival compared with placebo in a randomised …

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide.
Around half of patients with HCC will receive systemic therapies during their life span. The …

Background & Aims To compare the overall survival (OS) and disease progression free
survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are …